TCRT (Alaunos Therapeutics) Beginning Cash Position: $1.39 Mil (As of Mar. 2026)


TCRT Alaunos Therapeutics Inc TCRT
28 GF Score
Price $2.05
GF Value $0.68
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Alaunos Therapeutics Beginning Cash Position?

Alaunos Therapeutics TCRT -0.97% 28 Beginning Cash Position is $1.39 Mil as of Mar. 2026. GuruFocus rates TCRT with a GF Score™ of 28/100 and a GF Value™ of $0.68 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Alaunos Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $1.39 Mil.

Alaunos Therapeutics's quarterly Beginning Cash Position declined from Sep. 2025 ($2.78 Mil) to Dec. 2025 ($1.94 Mil) and declined from Dec. 2025 ($1.94 Mil) to Mar. 2026 ($1.39 Mil).

Alaunos Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($53.00 Mil) to Dec. 2024 ($6.06 Mil) and declined from Dec. 2024 ($6.06 Mil) to Dec. 2025 ($1.09 Mil).

Alaunos Therapeutics Beginning Cash Position Related Terms

Alaunos Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Alaunos Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alaunos Therapeutics Beginning Cash Position Chart

Alaunos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 115.07 76.05 53.00 6.06 1.09

Alaunos Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.09 3.58 2.78 1.94 1.39
TCRT
28GF Score
Alaunos Therapeutics Inc TCRT
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alaunos Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $1.39 Mil mean?
Alaunos Therapeutics (TCRT) has a Beginning Cash Position of $1.39 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alaunos Therapeutics and its competitors.
Is Alaunos Therapeutics' Beginning Cash Position too high?
Alaunos Therapeutics' current Beginning Cash Position is $1.39 Mil. Overall, Alaunos Therapeutics has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alaunos Therapeutics' Beginning Cash Position compare to DRMA and MBIO?
Alaunos Therapeutics' Beginning Cash Position of $1.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Alaunos Therapeutics and its competitors. Alaunos Therapeutics's current Beginning Cash Position is $1.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alaunos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Alaunos Therapeutics (TCRT) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.68, compared to a current price of $2.05 — trading 201.5% above its estimated fair value. The current Beginning Cash Position is $1.39 Mil. Alaunos Therapeutics' overall GF Score™ is 28/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Alaunos Therapeutics (TCRT), the current Beginning Cash Position is $1.39 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alaunos Therapeutics (TCRT) Overvalued in 2026?

Based on GuruFocus' analysis, Alaunos Therapeutics stock appears to be overvalued. The current stock price of $2.05 is trading 201.5% above its estimated GF Value™ of $0.68. GuruFocus considers Alaunos Therapeutics to be Significantly Overvalued.

Key valuation signals for TCRT:

  • Beginning Cash Position: $1.39 Mil
  • GF Value™: $0.68 vs. price of $2.05 (201.5% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the TCRT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alaunos Therapeutics Business Description

Address 501 East Las Olas Boulevard, Suite 300, Fort Lauderdale, FL, USA, 33301
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
28GF Score

Get the complete analysis for TCRT

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.05
Price
$0.68
GF Value